In Brief
The signals required for Breg cell differentiation in humans are currently unknown. Mauri and colleagues show that plasmacytoid dendritic cells, via the provision of IFN-a, govern the differentiation of immature B cells into regulatory B cells that restrain inflammation.
INTRODUCTION
Regulatory B (Breg) cells exhibit immunosuppressive functions via the release of IL-10, transforming growth factor (TGF)-b, and IL-35 and by induction of other regulatory cells Mauri and Nistala, 2014) . In healthy individuals, immature B cells have been shown to regulate T cell responses via the release of IL-10, suppressing T helper 1 (Th1) and Th17 cell differentiation, and by converting effector CD4 + T cells into FoxP3 + CD4 + regulatory T (Treg) cells (Blair et al., 2010; FloresBorja et al., 2013) . In several autoimmune diseases, including SLE and rheumatoid arthritis (RA), Breg cells are functionally and numerically impaired (Blair et al., 2010; Flores-Borja et al., 2013) . Signals required for the differentiation of human Breg cells remain poorly understood.
CD123
+ BDCA-2 + plasmacytoid dendritic cells (pDCs) are important drivers of innate and adaptive immune responses (McKenna et al., 2005; Reizis et al., 2011) . pDCs rapidly produce large amounts of interferon alpha (IFN-a) upon toll-like receptor (TLR) activation during viral infections or in response to neutrophil extracellular traps (NETs) (Gilliet et al., 2008; Hoffmann et al., 2015; Garcia-Romo et al., 2011; Swiecki and Colonna, 2015) . In SLE, neutrophils die upon exposure to SLE-derived anti-ribonucleoprotein antibodies and release NETs containing endogenous DNA as well as neutrophil proteins that enter pDC endocytic compartments and activate them to produce high amounts of IFN-a (Garcia-Romo et al., 2011; Lande et al., 2011) . IFN-a stimulates multiple cell types, including natural killer (NK) cells, monocytes, myeloid DCs, and T cells, to release a variety of pro-inflammatory cytokines (McKenna et al., 2005) . IFN-a produced by pDCs is pivotal in driving the maturation of B cells into plasmablasts (Jego et al., 2003; Poeck et al., 2004) . pDCs can induce the differentiation of IL-10-producing T cells and FoxP3 + Treg cells to counterbalance inflammatory responses and to prevent excess inflammation (Ito et al., 2007; Moseman et al., 2004; Swiecki and Colonna, 2015) . IFN-a-induced gene signature, together with defects in B cell function, is considered the hallmark of SLE (Bennett et al., 2003; Obermoser and Pascual, 2010) . In SLE, chronic activation of pDCs and other cells results in enhanced IFN-a and IFN-a/b receptor (IFN-a/bR) signaling on target cells (Rö nnblom and Eloranta, 2013) . Higher amounts of IFN-a production in SLE are associated with an accumulation of plasma cells, increased autoantibody, defective apoptotic cell clearance, and promotion of T-cell-dependent inflammation (Li et al., 2015; Pascual et al., 2006) . In lupus-prone transgenic mice, transient depletion of pDCs prior to disease initiation reduces autoantibody, type I IFN signature, and kidney pathology compared to undepleted mice (Rowland et al., 2014) . Similarly, IFN-a/bR blockade inhibits autoantibody production and protects young lupus-prone BXSB or MRL-Fas lpr mice from disease, highlighting a role for pDCs in the disease initiation (Baccala et al., 2012) . Furthermore, IRF8-deficient NZB mice, which lack pDCs, display a profound reduction in anti-nuclear, anti-chromatin, and anti-erythrocyte autoantibodies, as well as a significant reduction in kidney disease (Baccala et al., 2013) . In addition, mice lacking E2-2, a transcription factor that regulates pDC development, display impaired pDC function, a dramatic reduction in anti-DNA autoantibody production, and glomerulonephritis as well as ameliorated disease (Sisirak et al., 2014) . Several studies have linked type I IFNs with an increase in IL-10 production by B cells (Matsumoto et al., 2014; Schubert et al., 2015) . However, the role of pDCs and/or type I IFNs in determining whether a B cell becomes a Breg cell or an antibody-producing plasmablast remains unknown. Our data demonstrate that pDCs can generate plasmablasts that co-express IL-10, IL-6, and TNF-a and release antibody, as well as CD24 + CD38 (Jego et al., 2003) , we cocultured negatively isolated healthy B cells with autologous pDCs for 3 days with CpGC, a TLR9 agonist that stimulates both pDCs and B cells Figure 1B ).
In addition to expanding B cells with an immature phenotype that has previously been associated with Breg cells (Blair et al., 2010) , pDCs induced a 4-fold enrichment of IL-10-producing B cells compared to B cells stimulated with CpGC alone (Figure 1C ). An expansion of IL-10-producing B cell numbers was observed even at low ratios (up to 1:50 pDCs:B cells) (Figure S1E) . Analysis of the co-culture supernatants confirmed significantly increased amounts of IL-10 ( Figure 1D ). IL-10 + B cells generated by pDCs expressed higher Ki67 than IL-10 + B cells generated on stimulation with CpGC alone ( Figure S1F ). The majority of IL-10 + B cells induced by pDCs were CD24 + CD38 hi B cells, with a smaller percentage residing within the plasmablast population, also previously ascribed with regulatory capacity ( Figure 1E ; Matsumoto et al., 2014) . Figure S3A ). Figure 2C ). Enrichment in IL-10-producing B cells was noted in both subsets after culture with CpG and pDCs ( Figure 2D Figures 2F and 2G) ; however, pDC-generated plasmablasts comprised similar proportions of IL-10, TNF-a, or IL-6 single expressing cells and TNF-a+IL-10 or IL-6+IL-10 co-expressing cells (Figures 2F and 2G) . No IL-17, IFN-g, IL-1b, IL-2, IL-23, or IL-21 was detected by intracellular staining in the pDC-generated CD24 + CD38 hi B cells ( Figure S3G ). Data are expressed as mean ± SEM. See also Figure S3 . (Siegal et al., 1999) , the supernatants from CpGC-stimulated pDCs showed an abundance of IFN-a over other cytokines (Figure 3A) . CpGA and CpGB have been previously reported to differentially activate pDCs: CpGA stimulates pDCs to release IFN-a whereas CpGB induces the maturation of pDCs with minimal IFN-a production . This provided us with a useful tool to test whether IFN-a produced by CpG-activated pDCs is necessary for B cell IL-10 production. pDCs were activated with CpGA or CpGB, washed, and then cocultured with CpGB pre-activated B cells. pDCs and B cells stimulated with CpGC were used as a control. The results show that activation of pDCs with CpGA but not CpGB significantly expanded IL-10-producing B cells ( Figure S4F ). CD24 hi CD38 hi B cells have been reported to require CD40 signals to produce IL-10 (Blair et al., 2010) . Expression of CD154 (CD40L) on pDCs was upregulated after CpGC stimulation (Figure 3E) . Addition of anti-CD40L mAb to pDC-B cell co-cultures resulted in partial reduction of CD24 + CD38 hi Breg cells, whereas simultaneous neutralization of IFN-a/IFN-R2 and CD40L further decreased CD24 + CD38 hi Breg cell generation ( Figure 3F ). Blocking BAFF receptor in the pDC-B cell co-cultures had no effect on the differentiation of IL-10 + B cells. IL-10 + B cell induction was also independent of PD-1-PD-L1 or -PD-L2 interactions ( Figures  S4G-S4J ), reported to be important in the differentiation of Treg cells (Francisco et al., 2009 ).
pDC Activation Inversely Correlates with CD24 + CD38 hi Breg Cell Frequency Previous studies have reported that an elevated IFN-I gene signature correlates with disease severity (Bennett et al., 2003; Feng et al., 2006; Obermoser and Pascual, 2010) . We also observed that SLE patients with active disease (BILAG > 8) displayed an elevated IFN-I signature measured by the expression of MX1, MCL1, and IRF9, compared to patients with inactive disease (BILAG < 8) and healthy individuals (Figures 4A). pDCs from active SLE patients displayed higher relative expression of IFNA1 and IRF7, a transcription factor known to play a critical role in the induction of type I IFN (Honda et al., 2005) , as well as IL6 and IL12B, but not IL12A, compared to healthy individuals ( Figure S5A ). A significant increase in the amount of IFN-a was also detected in supernatants of CpGA-stimulated PBMCs from active SLE patients compared to healthy individuals ( Figure S5B hi Breg cell frequency and the activation of pDCs ex vivo in SLE patients. Unlike previous studies showing a numerical deficiency in the number of pDCs (Blanco et al., 2001; Cederblad et al., 1998) , the frequency of pDCs was unchanged in our cohort of patients ( Figure 4B ). The percentages of pDCs expressing Ki67, CD86, and CD80, hallmarks of TLR-induced pDC activation (McKenna et al., 2005) , were significantly increased in SLE patients with active disease compared to inactive patients or healthy controls (Figures 4B-4E ). Ex vivo expression of CD83, a DC maturation marker (Lechmann et al., 2002) , was undetectable in pDCs (data not shown). In addition, CD24 + CD38
hi Breg cell frequency inversely correlated with disease severity (Figures 4F), as well as with pDC activation status, measured by CD80 and CD86 expression, in active and inactive patients ( Figures 4G and 4H) . SLE patients were also grouped for analysis based on the expression of the IRF-9 as a marker of an IFN signature. Figure S5C shows that patients with a higher IFN signature (IFN hi ) have active disease, a higher frequency of activated pDCs (measured by the expression of CD80 and CD86), and a lower frequency of CD24 + CD38 hi Breg cells compared to patients with a low IFN-gene signature (IFN lo ). Similar results were obtained after segregating patients on MX1 and MCL1 expression levels (data not shown). Disease activity definitions and patient information are given in Table S1 .
SLE pDCs Failed to Promote Differentiation of CD24 + CD38 hi Breg Cells
Next, we investigated the functional outcome of pDC-B cell interactions in SLE patients. Using ImageStream technology, we visualized multiple pDC-B cell interactions in CpGC-stimulated PBMCs. No differences were found in the numbers of pDC-B cell conjugates in healthy and SLE PBMCs ( Figure S6A ). However, although healthy B cells interacting with pDCs expressed IL-10, SLE B cells interacting with pDCs did not ( Figure S6B ). Because patients with SLE are often lymphopenic (Rivero et al., 1978) , we were unable to obtain sufficient pDCs from SLE PBMCs to assess whether they induce Breg cells in co-cultures with autologous B cells. To circumvent this problem, we depleted pDCs from healthy or SLE PBMCs and measured the effect that pDC depletion had on the expansion of IL-10 + B cells or B cell subsets. ( Figure S6C confirms the depletion of pDCs from PBMCs by flow cytometry sorting.) It is noteworthy that, although SLE patients displayed lymphopenia, the pDC:B cell ratios in healthy and SLE PBMCs were comparable (data not shown). Frequencies of IL-10 + B cells were significantly reduced in pDC-depleted healthy PBMCs but not in SLE PBMCs (Figure 5A ). However, depletion of pDCs from CpGC-stimulated healthy and SLE PBMCs resulted in a significant reduction in the frequency of both CD24 + CD38 hi B cells and plasmablasts, compared to undepleted PBMCs ( Figure S6D ). IgG production by pDC-depleted PBMCs was decreased in both healthy and SLE PBMCs, whereas IgM levels were unaffected (Figures S6E and S6F) . Of note, no significant differences were observed in B cell subset frequencies ex vivo in healthy and SLE PBMCs ( Figure S6G ).
Our results suggest that the lack of CD24 + CD38 hi Breg cell induction observed in SLE could be the consequence of defective stimulation by pDCs. To evaluate this, healthy B cells were co-cultured either with pooled allogeneic healthy pDCs or with pDCs from SLE patients and stimulated with CpGC, and then CD24 + CD38 hi Breg cell induction was assessed by flow cytometry. pDCs from healthy individuals induced a 5-fold expansion gene expression ex vivo was comparable between healthy and SLE B cells ( Figure S6H ). These data suggest that both pDCs and B cells are defective in patients with SLE.
SLE B Cells Display an Altered Response to IFN-a Stimulation
To investigate whether in vivo exposure of B cells to high levels of IFN-a released by chronically activated pDCs could explain the reduced frequency of IL-10 + B cells in SLE, B cells were stimulated with CpGC and increasing doses of IFN-a. Healthy B-cell-derived IL-10 production increased up to 50,000 U/mL of IFN-a, but at higher concentrations IL-10 production was significantly reduced ( Figure 5C ). IFN-a induced only low levels of IL-10 production from SLE B cells, which did not increase with higher IFN-a concentrations ( Figure 5C Figures S7A and S7B ). In contrast, stimulation of both healthy and SLE B cells with increasing IFN-a concentrations continued to promote plasmablast differentiation, but not their expression of IL-10, even at the highest concentrations ( Figures S7C and S7D) . Engagement of IFN-a/bR by type I IFN results in the recruitment, phosphorylation, and nuclear translocation of signal transducer and activation of transcription proteins (STATs) and other transcription factors (Ivashkiv and Donlin, 2014) . In particular, IFN-a/bR signaling results in the recruitment of IRF9 and STAT1, which are involved in the transcription of interferon-stimulated genes (ISGs) and anti-nuclear antibody production in a mouse model of SLE (Thibault et al., 2008) , and STAT3, which is involved in the transcription of the IL-10 locus (Benkhart et al., 2000) . Ex vivo, the expression of IFR9 and total STAT1 (tSTAT1), but not total STAT3, were significantly increased in B cells from SLE patients compared to healthy controls (Figures 5D-5F ). In response to IFN-a, phosphorylation of STAT3, but not STAT1, was significantly decreased in SLE CD24 + CD38 hi B cells compared to healthy CD24 + CD38 hi B cells ( Figures 5G and 5H ). No differences between healthy and SLE were identified in the phosphorylation of STAT1 or STAT3 in the other B cell subsets (data not shown). In SLE B cells, these changes in total STAT1 and phosphorylation of STAT3 were reflected in a reduced frequency of single IL-10-producing B cells and an increase in the expression of TNF-a and IL-6, compared to healthy controls after in vitro stimulation of PBMCs with CpGC to activate pDCs ( Figures 5I  and 5J Figures 6D and 6E) . Because of the difficulties in obtaining sufficient pDC numbers from SLE patients, we could not assess whether SLE CD24 + CD38 hi B cells could suppress autologous pDC responses directly. As an alternative, we compared whether supernatants isolated from healthy or SLE immature B cells were able to inhibit IFN-a production by allogeneic healthy pDCs ( Figure 6F ). Supernatants from CD40L-stimulated healthy immature B cells, but not from SLE immature B cells, suppressed IFN-a production by allogeneic healthy pDCs ( Figure 6G ). These results highlight that Breg cells can regulate IFN-a production by pDCs in healthy individuals but not in SLE patients.
Rituximab Therapy Corrects pDC-Breg Cell Interactions
Patients treated with rituximab after B cell repopulation can be divided into two groups: those responding to rituximab (responders) and those not responding to rituximab (non-responders) therapy (Leandro et al., 2006) . We investigated whether the newly repopulated B cells in responding patients could differentiate into Breg cells and whether this would be accompanied by a normalization of pDC function. Newly repopulated B cells in responders expressed IRF9 and tSTAT1 comparable to healthy controls, whereas non-responders displayed higher expression of IRF9 and tSTAT1 (Figures 7A and 7B) . No differences were observed in the expression of tSTAT3 ( Figure 7C ). Upon stimulation with IFN-a, pSTAT1 expression increased and pSTAT3 decreased in CD24 + CD38 hi B cells from non-responders compared to responders and healthy individuals ( Figures 7D and 7E In responding patients, the restoration of CD24 + CD38 hi Breg cell function corresponded to a decrease in the activation of pDCs, as measured by CD80 and CD86 expression. In non-responding patients, the pDCs retained an activated phenotype ( Figures 7H and 7I) . Responders showed levels of Breg cells and pDC activation closer to healthy controls than non-responders ( Figures 7J and 7K) . In vitro depletion of pDCs from PBMCs of responders reduced the differentiation of IL-10 + B cells compared to undepleted PBMCs, indicating that the pDCs have reacquired the ability to induce CD24 + CD38 hi Breg cells in responding patients. In non-responders, depletion of pDCs from PBMCs had no effect on the expansion of CD24 + CD38 hi Breg cells ( Figure 7L ).
DISCUSSION
Experimental models of autoimmune diseases support a pivotal role for pro-inflammatory cytokines in the differentiation of Breg cells (Rosser et al., 2014; Yoshizaki et al., 2012) . The effect that inflammatory stimuli have on the differentiation of human Breg cells remains unclear. Here we report that TLR9-activated pDCs directly interact with immature B cells and promote their differentiation into CD24 + CD38 hi Breg cells as well as plasmablasts. pDCs play a pleiotropic role in the immune system, controlling both the initiation of pro-inflammatory responses necessary to clear infection and the differentiation of regulatory cells (Swiecki and Colonna, 2015) . Our data showing that pDCs are pivotal in the differentiation of CD24 an optimum amount of IFN-a by pDCs. This is in contrast to a previous study reporting that pDCs promote IL-10 production by B cells in an IFN-a-independent manner (Georg and Bekeredjian-Ding, 2012) . Discrepancies between the two studies could be due to the usage of different TLR9 agonists: Georg and Bekeredjian-Ding (2012) used CpGB, rather than CpGC, to stimulate pDCs and test the involvement of type I IFN in the pDC-B cell interaction. As previously reported, CpGB induces negligible amount of IFN-a by pDCs and preferentially promotes their maturation . The comparison of different TLR9 agonists in our study confirms that activation of pDCs with CpGC, but not CpGB, significantly expands IL-10-producing B cells via the release of IFN-a. Different concentrations of exogenous IFN-a added to B cells might also explain some of the differences reported. A role for IFN-a in the expansion of IL-10-producing B cells by pDCs cannot be entirely excluded without neutralization of IFN-a and IFN-a/bR in the pDC:B cell co-culture and this was not being tested in the study by Georg and Bekeredjian-Ding (2012) . Findings in a number of disease settings support a role for IFNa-producing pDCs in the differentiation of CD24 + CD38 hi Breg cells. In patients with human immunodeficiency virus (HIV) infection, IFN-a measured in the sera correlated with the disease severity and with increased number of CD24 hi CD38 hi B cells in circulation (Malaspina et al., 2006) . CD24 hi CD38 hi Breg cell enrichment in patients infected with HIV correlated with the viral load (Siewe et al., 2013 (Schubert et al., 2015) . In this study, the authors showed that B-cell-deficient mice are resistant to the IFN-b therapy, which otherwise treats experimental autoimmune encephalitis in wild-type mice, suggesting that B cells mediate the immunosuppressive effects of IFN-b therapy.
We found that the concentration of IFN-a determines whether an immature B cell develops into a CD24 + CD38 hi Breg cell or a plasmablast. At lower concentrations of IFN-a, B cells differentiate into both plasmablasts and CD24 + CD38 hi Breg cells, whereas at higher concentrations, the B cell response is channeled toward plasma cell maturation. A similar inhibitory effect was reported in another study showing that whereas lower concentrations of IFN-a promote FoxP3 expression, a high concentration (100,000 U/mL) inhibits the expression of FoxP3 on T cells (Shibuya and Hirohata, 2005) . Physiologically, the ability of moderate concentrations of IFN-a to induce both plasmablasts and CD24 + CD38 hi Breg cells might reflect the fact that an immune response to an infection requires both antibody production to eliminate invading pathogens and the generation of regulatory cells to prevent chronic inflammation. IFN-a-supported plasmablast and CD24 + CD38 hi Breg cell generation might also depend on the integration of other inflammatory signals, in particular the levels of CD40L expression, or the profile of cytokines produced over the course of the infection by contiguous or interacting cells. The finding that higher concentrations See also Figure S5 and Table S1 . Breg cells, and bias toward anti-nuclear antibody production and more severe disease, in patients with SLE who have an ''IFN gene signature.'' In MS patients, IFN-b treatment can induce the development of thyroid autoimmunity (Frisullo et al., 2014) and failure to respond to treatment in patients with an existing ''IFN gene signature'' (Verweij and Vosslamber, 2013) . IFN therapy in hepatitis C or chronic myelogenous leukemia (CML) patients can result in lupus-like symptoms (Tó thová , 2002; Wilson et al., 2002) . Therefore, it is possible that the induction of autoimmune-like disease after type I IFN therapy in these cases might be due to the high concentrations of exogenous type I IFN favoring plasmablasts over CD24 + CD38
hi Breg cell generation. Benkhart et al., 2000; Ivashkiv and Donlin, 2014; Luu et al., 2014) . This supports our findings showing increased amounts of IL-6 and TNF-a and lower amounts of IL-10, after stimulation via pDCs in SLE CD24 + CD38 hi B cells.
Our data suggest that the immune regulatory feedback between CD24 + CD38 hi Breg cells and pDCs that is in place in healthy individuals is dysfunctional in SLE patients but that this feedback is normalized in patients who respond to rituximab. It is tempting to suggest that when sufficient CD24 + CD38 hi Breg cells have been generated at a site of inflammation by IFN-a + pDCs or after CD40-CD40L interactions with T cells, for instance, Breg cells can then prevent pDCs from producing excessive IFN-a that would otherwise drive chronic inflammation. A similar feedback mechanism was previously shown in neonatal mice, where B cells producing IL-10 control the inflammatory response mounted by pDCs after the systemic administration of a TLR-9 agonist (Zhang et al., 2007) . However, in contrast to our results, this feature was restricted to neonatal B cells; TLR9 administration exacerbated inflammation in adult mice. Our data suggest that in adult humans, loss of feedback between CD24 + CD38 hi Breg cells and pDCs correlates with loss of tolerance that was restored in patients responding to rituximab. Thus, in addition to simply depleting pathogenic B cells and restoring Breg cell number and function, as has been previously reported (Anolik et al., 2007; Bosma et al., 2012) 
Image Stream
PBMCs were stimulated with CpGC for 6 hr. The cells were stained for surface expression of CD19 and BDCA-2, fixed, permeabilized, and stained for intracellular IL-10. The sample was processed on an Amnis ImagetreamX Imaging Flow Cytometer (MERK-Millipore) with a 403 objective. Raw image files were acquired with INSPIRE software. A compensation matrix was then applied to the acquired data to correct for spectral overlap followed by data analysis by IDEAS 5.0 software. A combined Area to Aspect Ratio dot plot was used to identify doublets, and a gradient RMS for the Brightfield was used to exclude out of focus cells. Cells were gated as CD19 + BDCA-2 + for pDC-B cell conjugate identification and assessed for the expression of IL-10.
(C) Bar chart shows percentage increase in IL-10 concentration in supernatants collected from cultures of healthy (n = 4) or SLE (n = 4) B cells with CpGC and 1,000 U/mL, 10,000 U/mL, 50,000 U/mL, or 100,000 U/mL of IFN-a, compared to IL-10 concentration in supernatants taken from B cell cultures with CpGC alone. Data are expressed as mean ± SEM. Data are representative of two independent experiments (D-H). See also Figure S6 and Table S1 . See also Figure S7 and Table S1 . (legend continued on next page) (QIAGEN). The relative expression level of specific transcripts was normalized with respect to the internal standard, b-actin. Relative expression was calculated against healthy control via the DDC T method.
Cell Signaling
PBMCs were surface stained with CD19, CD24, and CD38 antibodies in icecold PBS for 30 min, then rested for 1 hr in RPMI medium. Cells were stimulated by incubating with 10,000 U/mL exogenous IFN-a (PBL) for 1 or 5 min and then fixed with formaldehyde for 10 min at 37 C, washed with ice-cold PBS, and permeabilized with 90% ice-cold methanol for 20 min on ice. tSTAT1-PE, tSTAT3-AF647, pSTAT1-AF647, and pSTAT3-PE (BD Phosflow) were added to cells, for 1 hr at 37 C.
Statistical Analysis
Statistical analysis was performed with the Prism Software (GraphPad) by paired or unpaired t test or one-way or two-way ANOVA as specified, with Bonferroni correction for multiple comparisons. Correlations were assessed with Pearson's correlation coefficient. A p value of % 0.05 was considered significant. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one Data representative of three independent experiments are expressed as mean ± SEM. See also Figure S7 and Table S1 .
